Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Rigel Pharmaceuticals Inc RIGL

Healthcare Biotechnology
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the... see more

Recent & Breaking News (NDAQ:RIGL)

Rigel Provides Update on FDA Review of Fostamatinib for ITP

PR Newswire October 2, 2017

Stocks Under Scanner in the Generic Drugs Space -- Akorn, Pacira Pharma, Rigel Pharma, and Lipocine

PR Newswire September 26, 2017

Rigel to Present at Cantor Fitzgerald Global Healthcare Conference

PR Newswire September 19, 2017

22 Stocks Moving In Thursday's Pre-Market Session

Benzinga.com  August 31, 2017

Rigel Welcomes Brian Kotzin, M.D. to Board of Directors

PR Newswire August 25, 2017

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

PR Newswire August 18, 2017

Breakfast Technical Briefing on Generic Drugs Stocks -- Horizon Pharma, Mylan, Neurocrine Biosciences, and Rigel Pharma

PR Newswire August 14, 2017

Investor Network: Rigel Pharmaceuticals, Inc. to Host Earnings Call

Accesswire August 1, 2017

Rigel Announces Conference Call and Webcast to Report Second Quarter 2017 Financial Results

PR Newswire July 25, 2017

Technical Snapshots for These Generic Drugs Stocks -- Horizon Pharma, Mylan, Neurocrine Biosciences, and Rigel Pharma

PR Newswire July 10, 2017

Rigel Announces Oral Presentation of TAVALISSE™ (fostamatinib disodium) Phase 3 Clinical Data at the European Hematology Association 22nd Annual Congress

PR Newswire June 22, 2017

15 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  June 19, 2017

FDA Accepts Rigel's New Drug Application for TAVALISSE™ (fostamatinib disodium) for the Treatment of Chronic ITP

PR Newswire June 19, 2017

Breakfast Technical Briefing on Generic Drugs Stocks -- Innocoll, Rigel Pharma, Tetraphase Pharma, and Catalent

PR Newswire June 5, 2017

Rigel to Present at Jefferies 2017 Global Healthcare Conference

PR Newswire June 1, 2017

Rigel Announces First Quarter 2017 Financial Results and Provides Company Update

PR Newswire May 2, 2017

Investor Network: Rigel Pharmaceuticals, Inc. to Host Earnings Call

Accesswire May 2, 2017

Rigel Announces Tavalisse™ as Proprietary Name for Fostamatinib in the United States

PR Newswire April 27, 2017

Technical Reports on Generic Drugs Stocks -- Mylan, Allergan, Horizon Pharma, and Rigel Pharma

PR Newswire April 27, 2017

Rigel Announces Conference Call and Webcast to Report First Quarter 2017 Financial Results

PR Newswire April 25, 2017